We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

That shorter half-life makes it easier to adjust dosages to meet insulin needs, it maintains, while insulin glargine and insulin degludec have side effects ... in 2016 when Tresiba was launched ...

This is largely thanks to strong performances from GLP-1 analogue Victoza, insulin analogue Levemir and the 2015 launch of longer-acting insulin analogue Tresiba. Other companies rising strongly ...

A study confirmed that side effects like pancreatitis and kidney damage are possible while taking GLP-1s like Ozempic. Here's ...

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...

Herbal teas are often celebrated for their natural health benefits and soothing properties. However, it’s important to recognize that they can also have side effects and interact with medications, som ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Amy Schumer once hopped on board the Ozempic trend, but the side effects were so intense she had to stop. During a recent appearance on "The Howard Stern Show," the comedian, 43, opened up about ...

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

As scientists unravel how sleep benefits the body, a study in mice is highlighting the potential pitfalls of using Ambien and other sleeping pills.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...